Colorectal Great Debate: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Thursday, March 10, 2022

3:15 PM – 4:00 PM CST

Location:Trinity Ballroom

Moderator(s)

Martin Weiser, MD

Professor and Member
Memorial Sloan Kettering Cancer Center
New York, New York, United States
David Shibata, MD

Professor and Chairman, Department of Surgery; Executive Director, UTHSC Cancer Program
University of Tennessee Health Science Center
Memphis, TN, United States

Participants should be aware of the following financial/non-financial relationships:

Martin R. Weiser, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

David Shibata, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

There are now two large prospective randomized studies showing oncologic benefit to total neoadjuvant therapy. However, there remains controversy whether total neoadjuvant therapy represents over treatment. Understanding the pros and cons of total neoadjuvant therapy is critical for surgical oncologists, who are often the first point of contact for locally advanced rectal cancer patients. During this session, the published literatures will be reviewed; the controversies regarding total neoadjuvant therapy will be discussed; and the benefit and risk of total neoadjuvant therapy will be evaluated. CME

Presentations:

3:15 PM – 3:20 PM CST

Debate Intro and Pre-questions
3:20 PM – 3:35 PM CST

Total Neoadjuvant Therapy Should Be Used Routinely and Considered the New Standard for Locally Advanced (T3/4 or N+) Rectal Cancer (Pro)
Debater: Y. Nancy You, MD – University of Texas MD Anderson Cancer Center
3:35 PM – 3:50 PM CST

Total Neoadjuvant Therapy Represents Overtreatment and Should Be Used Selectively for Locally Advanced (T3/4 or N+) Rectal Cancer (Con)
Debater: Julio Garcia-Aguilar, MD, PhD – Memorial Sloan Kettering Cancer Center
3:50 PM – 4:00 PM CST

Rebuttals, Post-questions and Discussion